AI Article Synopsis
- Researchers generated cytotoxic T lymphocytes (CTL) from a patient’s blood to target their own malignant brain tumor by stimulating blood cells with specially treated melanoma cells instead of the brain tumor cells, which are hard to culture.
- The ideal condition for effective CTL induction was found to be a 25 to 1 ratio of activated T cells to supporting cells in the laboratory.
- The activated CTLs were effective in killing both the melanoma cells and the patient's tumor cells, suggesting that using these cross-reactive cells could be a promising treatment for malignant brain tumors.
Article Abstract
Cytotoxic T lymphocytes (CTL) against autologous malignant brain tumor were generated in peripheral blood lymphoid cells (PBL) prepared from a patient with a malignant brain tumor by stimulation of the cultured PBL for 7 days with attenuated crossreactive malignant melanoma (MM2) cells pretreated with mitomycin C. The crossreactive MM2 cells were effective for antigen stimulation for CTL induction in place of autologous glioblastoma cells, which are difficult to expand in culture. The optimal ratio between nylon wool-passed T lymphocytes and nylon wool-adherent accessory cells to induce CTL in the patient's PBL was found to be 25 to 1. In vitro-activated CTLs induced by MM2 were cytotoxic not only to MM2, but also to the autologous tumor cells in an HLA class I-restricted manner, and their surface phenotype was found to be CD3+ and CD8+. CTL therapy using cross-reactive allogeneic tumor cells as the stimulator could be clinically valuable to treat malignant brain tumors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921378 | PMC |
| http://dx.doi.org/10.1111/j.1349-7006.1997.tb00380.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!